BioMarin Pharmaceutical Inc. (BMRN) Reports Q1 Loss of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.39 --0%
EPS Growth %: +1,008.3%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
OMID, ACI, UNH, More
EPS Growth %: +1,008.3%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
OMID, ACI, UNH, More
Join SI Premium – FREE
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.04), $0.06 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $109.46 million versus the consensus estimate of $103.8 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- PepsiCo (PEP) Tops Q3 EPS by 4c, cuts EPS forecast
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
